Medical treatment for primary sclerosing cholangitis: Risk versus benefit

Hepatology

Volumn 32, Issue 4 I, 2000, Pages 871-872

  Angulo, Paul ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; LIVER ENZYME; PREDNISOLONE; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LIVER BIOPSY; NOTE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0033802365     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510320429     Document Type: Note

References (16)

1. Primary sclerosing cholangitis
2. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease
3. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
4. Drug therapy in the management of type 1 autoimmune hepatitis
5. Azathioprine for primary sclerosing cholangitis
6. Primary sclerosing cholangitis: Complete gross and histologic reversal after long-term steroid therapy
7. Positive corticosteroid response in early primary sclerosing cholangitis
8. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study
9. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo controlled trial
10. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period
11. Ursodiol for primary sclerosing cholangitis
12. The time course of histological progression in primary sclerosing cholangitis
13. A pilot double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss
14. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis
15. Oral budesonide in the treatment of patients with primary sclerosing cholangitis
16. Bone disease in liver transplant recipients: Incidence, timing and risk factors